Clinical Study

Role of Pentoxifylline and Sparfloxacin in Prophylaxis of Spontaneous Bacterial Peritonitis in Cirrhotic Patients

**Tarek Mohammed Mostafa,¹ Osama Mohamed Ibrahim,¹
Gamal Abd El-Khalek Badra,² and Mahmoud Samy Abdallah¹**

¹ Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt

² National Liver Institute, Menoufiya University, Shebeen El Kom 32111, Egypt

Correspondence should be addressed to Mahmoud Samy Abdallah; dr_samy777@yahoo.com

Received 17 January 2014; Accepted 19 February 2014; Published 6 March 2014

Academic Editors: L. Rodrigo, R. G. Romanelli, and W. Vogel

Copyright © 2014 Tarek Mohammed Mostafa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study was directed to evaluate the role of sparfloxacin and pentoxifylline in the prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients. Forty cirrhotic patients with ascites were included in the study. Patients were randomized into four groups in a blind fashion; each group consists of ten patients. Group one received ciprofloxacin (control group), group two received sparfloxacin, group three received pentoxifylline, and group four received a combination of sparfloxacin and pentoxifylline. Treatment duration was six months. Serum TNF- α level was the primary inflammatory marker of the study to evaluate the effect of the used medications. In group two, TNF- α level showed a statistically significant decrease in comparison with group one ($P = 0.001$), while in group three, TNF- α level showed nonsignificant difference in comparison with the control group ($P > 0.05$). In addition, group four showed a statistically significant decrease in TNF- α level compared to the other three groups ($P < 0.05$). The finding from our study indicates that sparfloxacin as well as pentoxifylline could be used in prophylaxis of spontaneous bacterial peritonitis. Combination of sparfloxacin and pentoxifylline showed some of synergism which may be useful in decreasing emergence of resistant strains.

1. Introduction

Spontaneous bacterial peritonitis (SBP) is a common and severe complication of cirrhotic patients having ascites with a prevalence rate between 10 and 30% characterized by spontaneous infection of ascitic fluid which occurs in the absence of any infection or perforation of intra-abdominal organs [1]. Approximately 20% of patients are already infected at the time of admission and nearly 50% develop an infection during hospitalization [2]. Patients with the greatest risk for the development of SBP are those who have recovered from the first episode. In these patients, the recurrence rate is very high; the probability of developing a new episode of SBP ranges from 40% to 70% within the first-year followup [3, 4]. SBP is now associated with in-hospital mortality rates ranging from 20% to 40% [5]. Furthermore, mortality rates one and two years after an episode of SBP are reported to

be 50–70% and 70–75%, respectively [6]. However, mortality after SBP is improved owing to early diagnosis and prompt treatment with empiric antibiotics. Bacterial translocation (BT) and migration of viable microorganisms from the intestinal lumen to the mesenteric lymph nodes and other extraintestinal sites have been postulated as the main mechanism in the pathogenesis of SBP [7–9]. Translocation of the enteric organisms to mesenteric lymph nodes is increased in patients with advanced cirrhosis and is reduced by selective intestinal decontamination [10]. According to European Association for the Study of the Liver (EASL) guidelines [11], the administration of prophylactic antibiotics reduces the risk of recurrent SBP. Norfloxacin (400 mg/day, orally) is the treatment of choice. Alternative antibiotics include ciprofloxacin (750 mg once weekly, orally) or cotrimoxazole (800 mg sulfamethoxazole and 160 mg trimethoprim daily, orally).

Sparfloxacin is a broad spectrum antibiotic, active against varieties of bacteria that are considered predisposing agents for SBP such as *E. coli*, *Klebsiellae*, *Enterobacter aerogenes*, *Shigella*, *Yersinia pestis*, and other Gram-negative microorganisms. In addition, it belongs to third generation fluoroquinolones (FQs) which have better activity against Gram-positive *Cocci* and anaerobes in comparison with ciprofloxacin. The difference in spectrum of activity is largely caused by increased activity against the DNA-gyrase of Gram-positive bacteria, rather than activity against Topoisomerase IV, which is the target in Gram-positive bacteria for the older quinolones [12, 13].

Pentoxifylline, [3,7-dimethyl-1-(5-oxohexyl)xanthine], is a methyl xanthine derivative with a significant protective effect in infection of Gram-negative sepsis and peritonitis in animal models [14]. It was found to have the property to block the inflammatory action of interleukin-1 (IL-1) and TNF- α on neutrophils and thus was able to diminish the tissue damage caused by neutrophils in morbid conditions like septic shock [15]. Pentoxifylline prevents bacterial translocation after intestinal obstruction in an experimental model as ischemic injury of intestinal mucosa plays a role in pathogenesis of bacterial translocation [16, 17]. In cirrhotic rats with ascites, pentoxifylline as well as norfloxacin reduces intestinal bacterial overgrowth, bacterial translocation, and spontaneous bacterial peritonitis [18]. In addition, it was presented that pentoxifylline, but not norfloxacin, reduces oxidative stress in cecal mucosal [18]. This may explain the expected beneficial role of pentoxifylline in the prevention of bacterial infection in patients with advanced cirrhosis.

Therefore, this research aimed to test new prophylactic therapies against microbes causing SBP. In this context, the role of both sparfloxacin and pentoxifylline as prophylactic therapy for SBP in patients with cirrhosis was investigated.

2. Materials and Methods

Forty patients with cirrhosis and ascites who had at least one previous episode of SBP were recruited from National liver Institute, Menoufiya University, Shebin El kom, Egypt. Patients were included in a randomized, blind, and controlled study. Diagnosis of cirrhosis was based on clinical, biochemical, and/or histological criteria. Inclusion criteria were age >18 and <80 years and participants gave their written informed consent. The protocol was approved by the ethics committee of National liver Institute, Menoufiya University, Shebin El kom, Egypt, with Institutional Review Board (IRB) protocol number 0063/2012. The diagnosis of SBP was confirmed if the ascitic fluid polymorphonuclear cell (PMN) count was greater than 250 mm^3 with or without positive culture and by absence of an intra-abdominal source of infection. Ascitic fluid cultures were performed using the conventional culture method and via inoculating 10 mL of fluid in aerobic and anaerobic blood culture bottles at the bedside.

Exclusion criteria included active gastrointestinal bleeding, encephalopathy (>grade 2), hepatocarcinoma or other malignancies, and allergy to quinolones.

At admission, patients were divided into four groups. Group one received ciprofloxacin 750 mg/week orally as prophylactic therapy ($n = 10$) (Ciprobay 750 mg tablet, Hikma pharma S.A.E under license of Bayer-Schering pharma, Germany) according to European Association for the Study of the Liver guidelines, group two received sparfloxacin 200 mg tablet (Spara 200 mg tablet, Global Nabi pharmaceuticals, Egypt) every other day for 10 days and then twice/week ($n = 10$), group three received pentoxifylline 400 mg tablet (Trental 400 mg SR tablet, Sanofi Aventis Egypt under license of Sanofi Aventis, Germany) once daily for 10 days and then twice/week, and group four received combination of sparfloxacin and pentoxifylline as scheduled above in groups two and three. The treatment was continued for six months. The etiology of cirrhosis for all patients encountered in this study was viral infection. Liver function was evaluated using Child-Pugh Classification [19]; all patients were classified as Child C.

At enrollment, physical examination, liver and renal function tests, sodium level, red and white blood cells count, platelets count, hemoglobin level, prothrombin time, and serum TNF- α concentrations were measured at baseline, three and six months after treatment.

Patients were followed up closely every month with careful assessment to rule out any complications such as fever, abdominal pain, or other symptoms or signs of infection. Study medication was discontinued in the case of recurrent SBP that represents end point of the trial. The drugs used in the study were withdrawn in patients suffering from other complications such as gastrointestinal bleeding or encephalopathy and receiving the standard treatment in each case.

About 10 mL of blood was taken from each patient by sterile venipuncture, without frothing and after minimal venous stasis using disposable syringes. About 3 mL of venous blood was delivered in a vacutainer serum separator tube. Immediate centrifugation at 3000 rpm to avoid contamination of the sample with erythrocyte arginase was done, and then serum samples were used for testing liver and renal function tests. (All kits used for biochemical analysis were supplied from Siemens Healthcare Diagnostics Products GmbH, Germany, Cat. No. OUHP 29). The optical density for all these parameters was measured using Shimadzu UV-PC 1601, spectrophotometer, Japan.

2.1. Measurement of Liver Function Parameters. Serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) were measured spectrophotometrically using kinetic method [20, 21], serum bilirubin level (total and direct) was measured spectrophotometrically using colorimetric (Diaz) method [22], measurement of serum albumin concentration was determined spectrophotometrically using modified bromocresol green colorimetric method [23], and prothrombin time was determined by coagulation method [24].

2.2. Measurement of Renal Function Parameters. Blood urea nitrogen was determined spectrophotometrically using enzymatic (fixed rate) UV method with urease and glutamate

TABLE 1: Demographic data of the participants.

Parameters	Group 1	Group 2	Group 3	Group 4	P value
Age (years)	50.8 ± 4.917	51.5 ± 4.196	50.5 ± 5.212	51.9 ± 5.087	0.50
Sex (male)	7 (70%)	8 (80%)	7 (70%)	7 (70%)	0.250
Weight (kilograms)	80.6 ± 6.26	80.7 ± 7.16	83.4 ± 5.62	80.75 ± 7.35	0.740
Smoking (%)	2 (20%)	2 (20%)	1 (10%)	2 (20%)	0.250
Diabetes (%)	2 (20%)	1 (10%)	2 (20%)	1 (10%)	0.333
Hypertension (%)	1 (10%)	2 (20%)	1 (10%)	1 (10%)	0.250

n = 10 for all groups.

dehydrogenase [25], serum creatinine concentration was determined spectrophotometrically using buffered kinetic Jaffé reaction without deproteinization method [26], and sodium level was determined colorimetrically [27].

2.3. Measurement of Hematological Parameters. About 2 mL of venous blood was delivered in a graduated vacutainer plastic tube containing 3.6 mg of potassium-ethylenediaminetetraacetic acid (K-EDTA) for complete blood count (CBC), haemoglobin (Hb) (Sysmex Automated Hematology Analyzer KX-21N, Japan), white blood cells (WBCs), red blood cells (RBCs), and platelets (PLTs) (Sysmex Corporation, Kobe 651-0073, Japan).

2.4. Measurement of TNF- α . About 3 mL of venous blood was drawn in EDTA tubes containing the protease inhibitor aprotinin for measurement of TNF- α . These tubes were kept refrigerated before blood sample collection. Serum was separated within 30 minutes after blood drawing and kept frozen at -70°C for measurement of TNF- α levels using Boster's Human TNF-alpha Elisa kit immunoassay (Boster Biological Technology, LTD, USA) using Biotek Elx 800-UV microtiter plate reader, USA.

2.5. Statistical Analysis. Statistical analysis of the data was done considering an alpha error of 0.05 with a 95% confidence interval. Data are presented by mean $\pm$ SD. Continuous data were tested using either paired *t*-test or one-way analysis of variance (ANOVA) as required for quantitative variables. Multiple comparisons were done using Tukey's method for all pairwise comparisons (Tukey's HSD). The statistical analysis was performed with IBM®SPSS Statistics V20 (SPSS Inc., USA).

3. Results

The period of recruitment was from December 2012 to November 2013. At National liver Institute, Menoufiya University, Shebin El kom, Egypt, 65 cirrhotic patients were enrolled in this study. There were 25 patients excluded from this study. (13 patients had hepatocellular carcinoma and 12 patients had severe gastrointestinal bleeding and subsequently died). Only 40 patients were randomized to this study (10 patients in each group). Demographic data of the participants defined as age, sex, weight, smoking, and other

systemic disorders such as diabetes and hypertension was demonstrated in Table 1.

Liver and renal function tests, sodium level, complete blood picture, and TNF- α at the baseline for the four groups presented by mean $\pm$ SD showed nonsignificant difference between groups (ANOVA, $P > 0.05$), therefore, any changes happened after treatment were due to the used medication not due to the individual variations as shown in Table 2. Clinical and laboratory characteristics of patients in the four groups three and six months after treatment presented by mean $\pm$ SD were demonstrated in Tables 3 and 4, respectively.

After six months of treatment, group two showed a statistically significant decrease in TNF- α level in comparison with the control group ($P = 0.001$) with nonsignificant differences in other laboratory data between it and the control group. They also showed a statistically significant decrease in TNF- α level in comparison with group three ($P = 0.002$), while group three showed nonsignificant change in TNF- α level compared to the control group ($P > 0.05$). In addition, group four showed a statistically significant decrease in TNF- α level in comparison with control group, group two, and group three ($P = 0.000$, $P = 0.006$, and $P = 0.000$), respectively.

For control group, TNF- α level three and six months after treatment showed a statistically significant decrease in comparison with its baseline data (paired *t*-test, $P = 0.01$ and $P = 0.000$), respectively. In addition, there was a statistically significant change six months after treatment compared to its level after three months of treatment (paired *t*-test, $P = 0.001$) with decrease of about 14.9%.

For group 2, TNF- α level three and six months after treatment showed a statistically significant decrease in TNF- α level in comparison with its baseline data (paired *t*-test, $P = 0.000$ and 0.000), respectively, but there was no significant change six months after treatment in comparison with its level after three months of treatment (paired *t*-test, $P > 0.05$).

For group three, TNF- α level, three and six months after treatment, showed a statistically significant decrease in TNF- α level in relation with its baseline data (paired *t*-test, $P = 0.000$ and 0.005), respectively, but there was no significant change six months after treatment in comparison with three months results (paired *t*-test, $P > 0.05$).

For group four, TNF- α level three and six months after treatment showed a statistically significant decrease in TNF- α level in comparison with its baseline data (paired *t*-test, $P = 0.000$ and $P = 0.000$), respectively, with decrease of about 48.4% and 64%, respectively. In addition, there was

TABLE 2: Selected clinical and laboratory features of patients at baseline.

Parameters	Group 1	Group 2	Group 3	Group 4	P value
AST (IU/L)	74.1 ± 16.23	78.1 ± 10.65	75.80 ± 11.47	78.10 ± 10.58	0.838
ALT (IU/L)	52.40 ± 14.27	54.40 ± 11.62	50.10 ± 10.68	49.8 ± 8.84	0.664
BIL-T (mg/dL)	2.46 ± 0.90	2.72 ± 0.77	2.57 ± 0.49	2.16 ± 0.71	0.412
BIL-D (mg/dL)	1.11 ± 0.37	1.31 ± 0.44	1.27 ± 0.44	1.21 ± 0.26	0.690
Albumin (g/dL)	2.55 ± 0.37	2.75 ± 0.35	2.60 ± 0.38	2.52 ± 0.34	0.970
PT (Sec.)	28.4 ± 6.70	28.0 ± 5.52	28.1 ± 4.33	27.6 ± 2.07	0.980
BUN (mg/dL)	71.0 ± 20.83	71.6 ± 20.94	71.4 ± 17.21	70.00 ± 11.81	0.992
s.Cr (mg/dL)	1.51 ± 0.35	1.48 ± 0.30	1.47 ± 0.35	1.56 ± 0.31	0.820
Sodium (mEq/L)	124.30 ± 6.85	126.5 ± 3.84	127.60 ± 5.78	128.1 ± 4.58	0.286
Hemoglobin (g/dL)	9.11 ± 0.92	9.03 ± 1.16	8.71 ± 0.97	8.75 ± 0.62	0.589
RBCs (10 ⁶ /uL)	3.22 ± 0.51	3.39 ± 0.43	3.26 ± 0.41	3.31 ± 0.25	0.795
WBCs (10 ³ /uL)	8.72 ± 1.70	8.95 ± 1.39	9.12 ± 1.34	9.23 ± 1.35	0.875
Platelets (10 ³ /uL)	77.04 ± 17.75	77.76 ± 8.75	77.76 ± 14.27	78.39 ± 11.17	0.795
TNF-α (pg/mL)	128.17 ± 28.63	113.37 ± 17.54	117.78 ± 22.03	115.38 ± 22.21	0.49

Data presented by mean ± SD; AST: aspartate transaminase; ALT: alanine aminotransferase; BIL-T: total bilirubin; BIL-D: direct bilirubin; PT: prothrombin time; BUN: blood urea nitrogen; s.Cr: serum creatinine; RBCs: red blood cells; WBCs: white blood cells; TNF-α: tumor necrosis factor alpha; pg/mL: picograms per milliliter.

TABLE 3: Selected clinical and laboratory features of patients 3 months after treatment.

Parameters	Group 1	Group 2	Group 3	Group 4	P value
AST (IU/L)	80.4 ± 14.2	83.5 ± 6.74	76.36 ± 11.51	73.50 ± 9.25	0.679
ALT (IU/L)	55.90 ± 10.29	50.40 ± 8.75	51.3 ± 5.79	52.70 ± 12.56	0.380
BIL-T (mg/dL)	2.36 ± 0.63	2.54 ± 0.64	2.57 ± 0.42	2.19 ± 0.69	0.681
BIL-D (mg/dL)	1.10 ± 0.29	1.13 ± 0.28	1.06 ± 0.22	1.11 ± 0.25	0.927
Albumin (g/dL)	2.64 ± 0.31	2.66 ± 0.22	2.65 ± 0.34	2.60 ± 0.28	0.394
PT (sec.)	29.50 ± 6.02	28.7 ± 6.75	29.7 ± 4.85	29.0 ± 2.45	0.158
BUN (mg/dL)	73.1 ± 15.64	72.1 ± 14.7	65.8 ± 12.23	71.5 ± 11.02	0.333
s.Cr (mg/dL)	1.63 ± 0.29	1.68 ± 0.45	1.19 ± 0.26	1.71 ± 0.36	0.508
Sodium (mEq/L)	127.1 ± 4.79	127.4 ± 4.48	127.90 ± 4.53	127.10 ± 4.79	0.973
Hemoglobin (g/dL)	9.01 ± 0.78	8.77 ± 0.64	9.16 ± 0.72	8.53 ± 0.45	0.797
RBCs (10 ⁶ /uL)	3.39 ± 0.25	3.28 ± 0.37	3.37 ± 0.29	3.33 ± 0.30	0.960
WBCs (10 ³ /uL)	7.71 ± 1.29	8.01 ± 1.04	7.84 ± 1.33	8.15 ± 1.35	0.984
Platelets (10 ³ /uL)	74.43 ± 12.31	75.33 ± 5.86	74.88 ± 8.90	75.04 ± 6.95	0.995
TNF-α (pg/mL)	99.09 ± 15.92	73.42 ± 11.49	99.35 ± 17.51	59.42 ± 8.37	0.000

Data presented by mean ± SD; AST: Aspartate transaminase; ALT: Alanine aminotransferase; BIL-T: Total bilirubin; BIL-D: Direct bilirubin; PT: Prothrombin time; BUN: Blood urea nitrogen; s.Cr: Serum creatinine; RBCs: Red blood cells; WBCs: White blood cells; TNF-α: Tumor necrosis factor alpha; pg/mL: picograms per milliliter.

a statistically significant decrease in TNF-α level six months after treatment compared to three months results (paired *t*-test, $P = 0.024$) with decrease of about 30%. The change in TNF-α level within the four treatment groups by time is demonstrated in Figure 1.

Serum creatinine level in group three after six months of treatment showed a statistically significant decrease in comparison with the control group ($P = 0.000$). This decrease in serum creatinine level in group three after six months of treatment was also statistically significant compared to group two and group four ($P = 0.000$ and $P = 0.000$), respectively.

For group 3, serum creatinine showed a statistically significant decrease three and six months after treatment in comparison with its baseline data (paired *t*-test, $P = 0.005$

and $P = 0.001$), respectively. There was also a statistically significant decrease in serum creatinine six months after treatment in comparison with three months results (paired *t*-test, $P = 0.036$). The change in serum creatinine level within the four treatment groups by time is demonstrated in Figure 2.

Hemoglobin level in group three showed nonsignificant increase in comparison with the control group six months after treatment ($P > 0.05$) with mean 10.28 ± 0.58 g/dL versus 8.80 ± 0.62 g/dL, respectively. This increase in hemoglobin level was statistically significant in relation with group two and group four ($P = 0.018$ and $P = 0.001$), respectively, after six months of treatment.

For group three, hemoglobin level showed nonsignificant increase three months after treatment in comparison with

TABLE 4: Selected clinical and laboratory features of patients 6 months after treatment.

Parameters	Group 1	Group 2	Group 3	Group 4	P value
AST (IU/L)	79.4 ± 10.08	86.0 ± 7.59	74.85 ± 8.92	82.85 ± 8.92	0.110
ALT (IU/L)	51.6 ± 8.06	51.9 ± 7.5	49.80 ± 10.49	56.8 ± 10.49	0.642
BIL-T (mg/dL)	2.40 ± 0.71	2.64 ± 0.64	2.47 ± 0.69	2.65 ± 0.61	0.767
BIL-D (mg/dL)	1.08 ± 0.35	1.16 ± 0.28	1.03 ± 0.25	1.28 ± 0.38	0.391
Albumin (g/dL)	2.71 ± 0.28	2.65 ± 0.25	2.67 ± 0.24	2.65 ± 0.21	0.012
PT (sec.)	30.9 ± 5.09	31.20 ± 5.25	30.7 ± 4.22	30.4 ± 2.07	0.886
BUN (mg/dL)	70.8 ± 13.77	72.9 ± 18.85	61.00 ± 9.03	72.7 ± 9.10	0.206
s.Cr (mg/dL)	1.68 ± 0.30	1.71 ± 0.39	0.99 ± 0.21	1.64 ± 0.47	0.001
Sodium (mEq/L)	128.4 ± 3.98	127.70 ± 4.64	126.60 ± 6.36	127.20 ± 3.79	0.994
Hemoglobin (g/dL)	8.80 ± 0.62	8.67 ± 0.48	10.28 ± 0.58	8.60 ± 0.47	0.001
RBCs (10 ⁶ /uL)	3.35 ± 0.2	3.22 ± 0.36	3.31 ± 0.34	3.26 ± 0.41	0.903
WBCs (10 ³ /uL)	7.45 ± 1.30	7.62 ± 0.91	7.26 ± 0.82	7.20 ± 0.88	0.926
Platelets (10 ³ /uL)	73.53 ± 9.45	73.261 ± 9.28	73.07 ± 9.70	73.44 ± 8.66	0.424
TNF-α (pg/mL)	84.27 ± 13.85	73.48 ± 7.27	91.19 ± 15.23	41.43 ± 7.07	0.000

Data presented by mean ± SD; AST: aspartate transaminase; ALT: alanine aminotransferase; BIL-T: total bilirubin; BIL-D: direct bilirubin; PT: prothrombin time; BUN: blood urea nitrogen; s.Cr: serum creatinine; RBCs: red blood cells; WBCs: white blood cells; TNF-α: tumor necrosis factor alpha; pg/mL: picograms per milliliter.

FIGURE 1: Changes in TNF-α level by treatment groups before treatment, three and six months after treatment. Data presented by mean ± SD. TNF-α level in the four groups decreases significantly ($P < 0.5$) three and six months after treatment in comparison with its level before treatment.

its baseline data (paired t -test, $P > 0.05$) with increase of about 5%, but there was a statistically significant increase six months after treatment compared to its baseline data and three months after treatment (paired t -test, $P = 0.000$ and $P = 0.000$), respectively, with increase of about 18% and 12.85%, respectively. The change in hemoglobin level within the four treatment groups by time is demonstrated in Figure 3.

FIGURE 2: Changes in serum creatinine by treatment groups before treatment, three and six months after treatment. Data presented by mean ± SD. * $P < 0.05$ in comparison with serum creatinine before treatment.

4. Discussion

This study was the first one that investigates the effect of pentoxifylline and sparfloxacin as a third generation fluoroquinolones antibiotic and a combination of pentoxifylline and sparfloxacin in prophylaxis of SBP. The results of

FIGURE 3: Changes in hemoglobin concentration by treatment groups before treatment, three and six months after treatment. Data presented by mean $\pm$ SD. * $P < 0.05$ in comparison with hemoglobin concentration before treatment.

the current study strongly support the efficacy of primary prophylactic therapy in patients with SBP. Sparfloxacin and pentoxifylline significantly reduce the probability of SBP, a common complication in patients with cirrhosis that carry a high mortality rate.

Serum TNF- α level was the primary inflammatory marker of the study to evaluate the effect of the used medications. Selection of serum TNF- α level based on Goldman and coworkers [28] data shows that bacterial translocation was associated with increased serum TNF- α . Bacterial translocation is one of the main events in the pathogenesis of spontaneous bacterial peritonitis [29]. Some of the factors involved in BT are bacterial-dependent (virulence and overgrowth), while others are related to intestinal hypomotility, permeability, mucosal oedema, structural changes in the intestinal wall, and mucosal peroxidation [29]. Selective intestinal decontamination with poorly absorbable antibiotics decreases intestinal bacterial overgrowth (IBO) and BT in experimental and human cirrhosis, with subsequent prevention of SBP [18].

Sparfloxacin showed a statistically significant decrease in TNF- α level in comparison with ciprofloxacin. This may be due to broad spectrum activity of sparfloxacin against varieties of bacteria including Gram-negative and Gram-positive bacteria and some anaerobes [12, 13] in comparison with ciprofloxacin especially with increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis [30]. The basic mechanisms underlying FQs immunomodulatory activity have not been elucidated in a comprehensive and satisfying manner. Sparfloxacin exerts its immunomodulatory

activities by inhibition of dipeptidyl peptidase IV enzyme (DPP IV) in a dose-dependent manner [31]. Sparfloxacin was given as 200 mg every other day for 10 days as an initial dose then twice/week based on prolonged elimination half-life in cases of renal insufficiency after a single oral dose [32]. Also endotoxin, an active component in the outer membrane of the gram negative bacteria, decreases the biliary excretion of sparfloxacin and its glucuronide probably due to impairment of their hepatobiliary transport systems and renal handling [33]. The long elimination half-life could be an advantage, resulting in bactericidal concentrations for prolonged periods, which would make twice/week treatment possible.

Pentoxifylline showed no difference in TNF- α level in comparison with ciprofloxacin. This difference in TNF- α level may be statistically nonsignificant, but it may be clinically important to keep patients away from antibiotic resistance and adverse effects. The beneficial effect of pentoxifylline on decreasing bacterial translocation is its ability to enhance leukocyte functions. It is well known that translocated bacteria can be cleared by intestinal and mesenteric macrophages [34–36]. Then, translocated bacteria can be cleared by increased mesenteric leukocyte functions mediated by pentoxifylline [37–39]. Pentoxifylline also inhibits the production of TNF- α by endotoxin-stimulated monocytes/macrophages at the transcriptional level and is effective in reducing serum TNF- α level in mice with endotoxic shock [40], so pentoxifylline as anti-TNF- α agent could decrease bacterial translocation as previously mentioned by Goldman and coworkers [28]. Heller and coworkers [41] have shown that pentoxifylline improves bacterial clearance during hemorrhage and endotoxemia and these authors suggested that pentoxifylline could reduce the risk of bacterial infections by attenuating bacterial colonization of organs. Further investigations showed that pentoxifylline potentially affects endotoxin-induced release of TNF- α which plays an important role in superantigen-mediated shock [18]. Other beneficial effects of pentoxifylline include improvement in microcirculation that leads to increased bactericidal effect of chemotherapeutic agents [42]. In addition, pentoxifylline promotes physiological changes in fibroblasts resulting in better wound healing [42]. This apparently surprising finding in inhibition of TNF- α by pentoxifylline is in disagreement with the previous reported by Lebrech et al., (2010) showing the failure of pentoxifylline to decrease serum TNF- α levels in patients with advanced cirrhosis [43].

The decrease in serum creatinine level that happened by pentoxifylline in comparison with ciprofloxacin, sparfloxacin, and combination of pentoxifylline and sparfloxacin may be due to improving the renal microcirculation and hemodynamics by pentoxifylline [44], not due to its effect on TNF- α synthesis [45] as demonstrated by Akriviadis et al. This explains the improvement in serum creatinine level by pentoxifylline with increasing the duration of therapy as six months results was better than three months results which independent of its effect on TNF- α . This potential primary protective effect of pentoxifylline on renal function is confirmed by its efficacy on prevention of hepatorenal syndrome in severe alcoholic hepatitis patients [46] which occurs in

the setting of a decrease in effective arterial blood volume, as indicated by a marked activation of vasoconstrictor systems, and increased serum and ascitic fluid cytokines level [47]. On the other hand, there was no improvement in serum creatinine level in the other three groups. Even patients who received combination of both sparfloracin and pentoxifylline did not show any improvement in serum creatinine level. This may be due to the side effects of sparfloracin on the renal function. The increase in hemoglobin level shown by pentoxifylline in comparison with other groups may be due to keeping patients away from antibiotics side effects. In addition, pentoxifylline can improve hemoglobin levels in renal failure patients with erythropoietin-resistant anemia [48].

Pentoxifylline was given as 400 mg once daily for 10 days as an initial dose and then twice/week. The choice of this dosing pattern is based on the hypothesis of the decrease in the total plasma clearance and the increase in the absolute bioavailability of pentoxifylline and its active metabolite by six-eight-fold in cirrhotic patient after oral administration of the sustained-release tablet [49]. In addition, inhibition of these cytokines by pentoxifylline evidently occurs at the transcriptional level and can last for up to five days after the final pentoxifylline dose [50]. Since pentoxifylline prevents intestinal bacterial translocation [51], it could be another promising approach in prophylaxis of spontaneous bacterial peritonitis.

Combination of sparfloracin and pentoxifylline showed a statistically significant decrease in TNF- α level in comparison with the other three groups. This may be due to the synergistic effect between pentoxifylline and fluoroquinolones antibiotics resulting in the inhibition of TNF- α as demonstrated by Bailly et al. [52]. The synergistic effect between pentoxifylline and sparfloracin may be due to improvement of microcirculation by pentoxifylline resulting in increasing the bactericidal effect of chemotherapeutic agents [42]. The decrease in TNF- α level was better after six months of treatment than after three months in patients who received combination of pentoxifylline and sparfloracin in comparison with group two and group three. This may be due to the synergistic effect between pentoxifylline and sparfloracin. It is possible that the shorter followup in our study (six months) may be responsible for the absence of mortality found in this study. Probably the improvement in survival observed in the current study could be related to the reduction of bacterial translocation and the subsequent amelioration of hemodynamic alterations, reducing the risk of bleeding, encephalopathy and infections.

5. Conclusion

According to the data obtained by this study, sparfloracin could be used in prophylaxis of spontaneous bacterial peritonitis due to its broad spectrum of activity against Gram-positive and Gram-negative bacteria and some anaerobes. Pentoxifylline as tumor necrosis factor inhibitor could be another promising approach reported to hinder BT and to be used as prophylactic therapy agent for spontaneous bacterial peritonitis. Sparfloracin and pentoxifylline show synergistic effect which may be useful in decreasing emergence of

resistant strains. The risk to develop bacterial resistance seems to have a low clinical impact compared to the observed benefit. The efficacy of both sparfloracin and pentoxifylline in the prophylaxis of SBP in cirrhotics needs further prospective studies on large scale.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgment

The authors are grateful to the National liver Institute, Menoufiya University, Shebin El kom, Egypt, for providing the facilities to carry out these studies.

References

- [1] A. Rimola and M. Navasa, "Infections in liver disease," in *Oxford Textbook of Clinical Hepatology*, J. Bircher, J. P. Benhamou, N. McIntyre, M. Rizzetto, and J. Rode's, Eds., pp. 1861–1876, Oxford University Press, Oxford, UK, 2nd edition, 1999.
- [2] J. Lata, O. Stiburek, and M. Kopacova, "Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis," *World Journal of Gastroenterology*, vol. 15, no. 44, pp. 5505–5510, 2009.
- [3] B. A. Runyon, "Spontaneous bacterial peritonitis: an explosion of information," *Hepatology*, vol. 8, no. 1, pp. 171–175, 1988.
- [4] L. Titó, A. Rimola, P. Gines, J. Llach, V. Arroyo, and J. Rodes, "Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors," *Hepatology*, vol. 8, no. 1, pp. 27–31, 1988.
- [5] P. J. Thuluvath, S. Morss, and R. Thompson, "Spontaneous bacterial peritonitis—in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998," *The American Journal of Gastroenterology*, vol. 96, no. 4, pp. 1232–1236, 2001.
- [6] A. Rimola, G. García-Tsao, M. Navasa et al., "Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document," *Journal of Hepatology*, vol. 32, no. 1, pp. 142–153, 2000.
- [7] C. Guarner and G. Soriano, "Bacterial translocation and its consequences in patients with cirrhosis," *European Journal of Gastroenterology and Hepatology*, vol. 17, no. 1, pp. 27–31, 2005.
- [8] R. D. Berg and A. W. Garlington, "Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model," *Infection and Immunity*, vol. 23, no. 2, pp. 403–411, 1979.
- [9] B. A. Runyon, S. Squier, and M. Borzio, "Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis," *Journal of Hepatology*, vol. 21, no. 5, pp. 792–796, 1994.
- [10] J. Fernández, M. Navasa, J. Gómez et al., "Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis," *Hepatology*, vol. 35, no. 1, pp. 140–148, 2002.
- [11] P. Ginès, P. Angeli, K. Lenz et al., "EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis," *Journal of Hepatology*, vol. 53, no. 3, pp. 397–417, 2010.

- [12] E. Pestova, J. J. Millichap, G. A. Noskin, and L. R. Peterson, "Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones," *Journal of Antimicrobial Chemotherapy*, vol. 45, no. 5, pp. 583–590, 2000.
- [13] D. C. Hooper, "Mechanisms of action and resistance of older and newer fluoroquinolones," *Clinical Infectious Diseases*, vol. 31, supplement 2, pp. S24–S28, 2000.
- [14] H. Harada, A. Ishizaka, M. Yonemaru et al., "The effects of aminophylline and pentoxifylline on multiple organ damage after *Escherichia coli* sepsis," *The American Review of Respiratory Disease*, vol. 140, no. 4, pp. 974–980, 1989.
- [15] G. E. Chalkiadakis, A. Kostakis, P. E. Karayannacos et al., "Pentoxifylline in the treatment of experimental peritonitis in rats," *Archives of Surgery*, vol. 120, no. 10, pp. 1141–1144, 1985.
- [16] M. M. Schonharting and U. F. Schade, "The effect of pentoxifylline in septic shock—new pharmacologic aspects of an established drug," *Journal of Medicine*, vol. 20, no. 1, pp. 97–105, 1989.
- [17] D.-Z. Xu, Q. Lu, R. Kubicka, and E. A. Deitch, "The effect of hypoxia/reoxygenation on the cellular function of intestinal epithelial cells," *The Journal of Trauma: Injury, Infection and Critical Care*, vol. 46, no. 2, pp. 280–285, 1999.
- [18] F. Corradi, C. Brusasco, J. Fernández et al., "Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites," *Digestive and Liver Disease*, vol. 44, no. 3, pp. 239–244, 2012.
- [19] R. N. H. Pugh, I. M. Murray-Lyon, and J. L. Dawson, "Transection of the oesophagus for bleeding oesophageal varices," *The British Journal of Surgery*, vol. 60, no. 8, pp. 646–649, 1973.
- [20] H. U. Bergmeyer, M. Hørdér, and R. Rej, "International Federation of Clinical Chemistry (IFCC) scientific committee, analytical section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC method for aspartate aminotransferase (L-aspartate: 2-oxoglutarate aminotransferase, EC 2.6.1.1)," *Journal of Clinical Chemistry and Clinical Biochemistry*, vol. 24, no. 7, pp. 497–510, 1986.
- [21] H. U. Bergmeyer, M. Horder, and R. Rej, "International Federation of Clinical Chemistry (IFCC) scientific committee, analytical section: approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase (L-alanine: 2-oxoglutarate aminotransferase, EC 2.6.1.2)," *Journal of Clinical Chemistry and Clinical Biochemistry*, vol. 24, no. 7, pp. 481–495, 1986.
- [22] B. T. Doumas, P. P. Kwok-Cheung, and B. W. Perry, "Candidate reference method for determination of total bilirubin in serum: development and validation," *Clinical Chemistry*, vol. 31, no. 11, pp. 1779–1789, 1985.
- [23] B. T. Doumas, W. A. Watson, and H. G. Biggs, "Albumin standards and the measurement of serum albumin with bromocresol green," *Clinica Chimica Acta*, vol. 31, no. 1, pp. 87–96, 1971.
- [24] A. J. Quick, "Quick on "Quick agglutination venostasis" bleeding time technique," *The Journal of Laboratory and Clinical Medicine*, vol. 26, article 1812, 1973.
- [25] A. J. Taylor and P. Vadgama, "Analytical reviews in clinical biochemistry: the estimation of urea," *Annals of Clinical Biochemistry*, vol. 29, no. 3, pp. 245–264, 1992.
- [26] K. Spencer, "Analytical reviews in clinical biochemistry: the estimation of creatinine," *Annals of Clinical Biochemistry*, vol. 23, no. 1, pp. 1–25, 1986.
- [27] R. F. Henry, D. C. Cannon, and J. W. Winklemen, *Clinical Chemistry: Principles and Techniques*, Harper and Row, Hagerstown, Md, USA, 2nd edition, 1974.
- [28] G. Goldman, D. Soffer, L. Heller, D. Aderka, A. Lahat, and J. M. Klausner, "Tumour necrosis factor mediates bacterial translocation after haemorrhagic shock and endotoxaemia," *European Journal of Surgery*, vol. 167, no. 4, pp. 299–304, 2001.
- [29] J. Fernández, M. Navasa, J. Gómez et al., "Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis," *Hepatology*, vol. 35, no. 1, pp. 140–148, 2002.
- [30] E. Cholongitas, G. V. Papatheodoridis, A. Lahanas, A. Xanthaki, C. Kontou-Kastellanou, and A. J. Archimandritis, "Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis," *Liver International*, vol. 25, no. 1, pp. 57–61, 2005.
- [31] S. Saleh, M. Mohammad, S. Mashallah et al., "Inhibition of DPP IV is a suggested mechanism of the immunomodulatory effects of sparfloxacin," *Scientific Research and Essays*, vol. 7, no. 3, pp. 310–317, 2012.
- [32] Y. Matsunaga, H. Miyazaki, N. Nomura, and M. Hashimoto, "Disposition and metabolism of [14C]sparfloxacin after repeated administration in the rat," *Arzneimittel-Forschung*, vol. 41, no. 7, pp. 760–763, 1991.
- [33] M. Nadai, Y. L. Zhao, L. Wang et al., "Endotoxin impairs biliary transport of sparfloxacin and its glucuronide in rats," *European Journal of Pharmacology*, vol. 432, no. 1, pp. 99–105, 2001.
- [34] G. A. P. Nieuwenhuijzen, Y. Haskel, Q. Lu et al., "Macrophage elimination increases bacterial translocation and gut-origin septicemia but attenuates symptoms and mortality rate in a model of systemic inflammation," *Annals of Surgery*, vol. 218, no. 6, pp. 791–799, 1993.
- [35] J. V. Reynolds, P. Murchan, H. P. Redmond et al., "Failure of macrophage activation in experimental obstructive jaundice: association with bacterial translocation," *The British Journal of Surgery*, vol. 82, no. 4, pp. 534–538, 1995.
- [36] X. Wang, R. Andersson, V. Soltesz, P. Leveau, and I. Ihse, "Gut origin sepsis, macrophage function, and oxygen extraction associated with acute pancreatitis in the rat," *World Journal of Surgery*, vol. 20, no. 3, pp. 299–308, 1996.
- [37] K. Josaki, J. Contrino, J. Kristie, P. Krause, and D. L. Kreutzer, "Pentoxifylline-induced modulation of human leukocyte function in vitro," *The American Journal of Pathology*, vol. 136, no. 3, pp. 623–630, 1990.
- [38] P. J. Krause, J. Kristie, W.-P. Wang et al., "Pentoxifylline enhancement of defective neutrophil function and host defense in neonatal mice," *The American Journal of Pathology*, vol. 129, no. 2, pp. 217–222, 1987.
- [39] C. Wenisch, K. Zedtwitz-Liebenstein, B. Parschalk, and W. Graninger, "Effect of pentoxifylline in vitro on neutrophil reactive oxygen production and phagocytic ability assessed by flow cytometry," *Clinical Drug Investigation*, vol. 13, no. 2, pp. 99–104, 1997.
- [40] U. F. Schade, "Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor," *Circulatory Shock*, vol. 31, no. 2, pp. 171–181, 1990.
- [41] S. Heller, K. Weber, A. Heller, R. Urbaschek, and T. Koch, "Pentoxifylline improves bacterial clearance during hemorrhage and endotoxemia," *Critical Care Medicine*, vol. 27, no. 4, pp. 756–763, 1999.

- [42] V. K. Shukla, A. K. Ojha, M. Pandey, and B. L. Pandey, "Pentoxifylline in perforated peritonitis: results of a randomised, placebo controlled trial," *European Journal of Surgery*, vol. 167, no. 8, pp. 622–624, 2001.
- [43] D. Lebrech, D. Thabut, F. Oberti et al., "Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis," *Gastroenterology*, vol. 138, no. 5, pp. 1755–1762, 2010.
- [44] E. Ernst, "Pentoxifylline for intermittent claudication—a critical review," *Angiology*, vol. 45, no. 5, pp. 339–345, 1994.
- [45] E. Akriviadis, R. Botla, W. Briggs, S. Han, T. Reynolds, and O. Shakil, "Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial," *Gastroenterology*, vol. 119, no. 6, pp. 1637–1648, 2000.
- [46] J. Han, P. Thompson, and B. Beutler, "Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway," *The Journal of Experimental Medicine*, vol. 172, no. 1, pp. 391–394, 1990.
- [47] M. Navasa, A. Follo, X. Filella et al., "Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality," *Hepatology*, vol. 27, no. 5, pp. 1227–1232, 1998.
- [48] A. Cooper, A. Mikhail, M. W. Lethbridge, D. M. Kemeny, and I. C. Macdougall, "Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure," *Journal of the American Society of Nephrology*, vol. 15, no. 7, pp. 1877–1882, 2004.
- [49] A. Rames, J.-M. Poirier, F. LeCoz et al., "Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients," *Clinical Pharmacology and Therapeutics*, vol. 47, no. 3, pp. 354–359, 1990.
- [50] P. Neuner, G. Klosner, E. Schauer et al., "Pentoxifylline in vivo down-regulates the release of IL-1 β , IL-6, IL-8 and tumour necrosis factor- α by human peripheral blood mononuclear cells," *Immunology*, vol. 83, no. 2, pp. 262–267, 1994.
- [51] F. Corradi, J. Fernandez, M. Navasa et al., "Pentoxifylline prevents Small Intestinal Bacterial Overgrowth (SIBO), Bacterial Translocation (BT), and Spontaneous Bacterial Peritonitis (SBP) in experimental cirrhosis," *Journal of Hepatology*, vol. 40, supplement 1, p. 14, 2004.
- [52] S. Bailly, M. Fay, Y. Roche, and M. A. Gougerot-Pocidalo, "Effects of quinolones on tumor necrosis factor production by human monocytes," *International Journal of Immunopharmacology*, vol. 12, no. 1, pp. 31–36, 1990.